ABSI — Absci Corp
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1672688 ·
Last close
$7.58
Market Cap
$1.31B
52W High
$12.55
52W Low
$2.24
ADV30
4,259,299
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 304,000 | — | -34,994,000 | -33,300,000 | 239,574,000 | 13,359,000 | 20,897,000 |
| Jun 2026 | 318,000 | — | -34,158,000 | -33,210,000 | 268,917,000 | 107,865,000 | 22,786,000 |
| Mar 2026 | 215,000 | — | -30,846,000 | -29,599,000 | 195,593,000 | 8,627,000 | 23,622,000 |
| Dec 2025 | 650,000 | — | -36,142,000 | -29,562,000 | 216,297,000 | 20,025,000 | 26,848,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-112,520,000
Investing CF
$-16,073,000
Financing CF
$116,140,000
CapEx
$-1,002,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-720,893,000
Inventory
—
Receivables
$1,000,000
ST Investments
$160,370,000
EBIT TTM
$-125,706,000
Pretax Income TTM
$-125,757,000
Interest Exp TTM
$51,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,487,000
EBITDA
$-124,500,000
Free Cash Flow
$-50,902,876
Enterprise Value
$1,289,261,056
Total Cash
$173,728,992
Total Debt
$3,288,000
Shares Out
172,745,810
Trailing EPS
$-0.79
Book Value
$1.27
ROE
-58.6%
ROA
-34.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,800,000 | -125,418,000 | -115,183,000 | 216,297,000 | 26,848,000 | 189,449,000 | -92,925,000 |
| Dec 2024 | 4,534,000 | -108,888,000 | -103,106,000 | 213,608,000 | 34,475,000 | 179,133,000 | -72,402,000 |
| Dec 2023 | 5,718,000 | -94,180,000 | -110,566,000 | 217,298,000 | 41,122,000 | 176,176,000 | -64,636,000 |
| Dec 2022 | 5,747,000 | -106,750,000 | -104,904,000 | 321,008,000 | 46,594,000 | 274,414,000 | -81,339,000 |
TTM Snapshot
Revenues TTM
$1,561,000
NetIncome TTM
$-121,077,000
OpCashFlow TTM
—
Assets (Latest)
$268,917,000
Forward EPS
$-0.70
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $8.18 · call volume: 1,320 · put volume: 270
Expected Move to 2026-12-18:
±$3.97
(48.53%) —
implied range
$4.21 –
$12.15
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | $1.37B | $9.78 | — |
| CLDX | Celldex Therapeutics, Inc. | $2.20B | $28.04 | — |
| OABI | OmniAb, Inc. | $736.59M | $5.05 | — |
| NEOG | NEOGEN CORP | $2.38B | $10.90 | — |
| QDEL | QuidelOrtho Corp | $677.21M | $9.87 | — |
News headlines (Yahoo Finance, 1h cache)
Absci Corp. (ABSI) Gets Downgraded. Here’s How Much
2026-11-17 01:43 · Yahoo
Absci (ABSI) Advances ABS 201 Plans, Is The 43% Discount Justified?
2026-11-13 23:18 · Yahoo
Absci Corp (ABSI) Q3 2026 Earnings Call Highlights: ABS-201 Momentum Builds as Cash Runway ...
2026-11-12 23:08 · Yahoo
Absci Corporation Q3 2026 Earnings Call Summary
2026-11-12 17:58 · Yahoo
Absci (ABSI) Q3 2026 Earnings Call Transcript
2026-11-12 17:14 · Yahoo
Absci Q3 Earnings Call Highlights
2026-11-12 16:15 · Yahoo
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 12:35 · Yahoo
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
2026-11-12 12:05 · Yahoo
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
2026-11-12 12:00 · Yahoo
Absci (ABSI) Stock Could Be Overvalued Given Its Book Value Gap
2026-11-06 22:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.